Neoantigen × AI
Daily research signal
TRACKING / TRIAL TRACKER

NCT03357757 — AHS Cancer Control Alberta cancer immunotherapy trial

Avelumab With Valproic Acid in Virus-associated Cancer

TrackingPhase 2CompletedRegistry updated 4 Nov 2026
Phase 2phaseCompletedregistry status39enrollment2022-03-30primary completion

Registry IDNCT03357757 ↗
Lead sponsorAHS Cancer Control Alberta
CollaboratorsEMD Serono
PhasePhase 2
StatusCompleted
IndicationCancer That is Associated With a Chronic Viral Infection, p16 Positive SCCHN, Squamous Cell Carcinoma of the Cervix, p16 Positive Squamous Cell Carcinoma of the Vagina or Vulva, p16 Positive Squamous Cell Carcinoma of the Penis, p16 Positive Squamous Cell Carcinoma of the Anus or Anal Canal, EBER Positive NPC, EBER Positive Hodgkins and Non-hodgkins Lymphona
Enrollment39 participants
Start date2018-02-07
Primary completion2022-03-30
Last registry update4 Nov 2026

Every field above is mirrored from the study record on ClinicalTrials.gov (NCT03357757), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.

No modality, tumor or player hub covers this study yet. Browse the field map for the axes the daily brief does track.

What phase is NCT03357757?

NCT03357757 (Avelumab With Valproic Acid in Virus-associated Cancer) is registered on ClinicalTrials.gov as Phase 2, sponsored by AHS Cancer Control Alberta.

Is NCT03357757 recruiting?

As of the 2026-11-04 registry update, NCT03357757 is listed as "Completed". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.

Who is running NCT03357757?

The lead sponsor is AHS Cancer Control Alberta. Collaborators: EMD Serono.

What condition does NCT03357757 study?

The registered conditions are Cancer That is Associated With a Chronic Viral Infection, p16 Positive SCCHN, Squamous Cell Carcinoma of the Cervix, p16 Positive Squamous Cell Carcinoma of the Vagina or Vulva, p16 Positive Squamous Cell Carcinoma of the Penis, p16 Positive Squamous Cell Carcinoma of the Anus or Anal Canal, EBER Positive NPC, EBER Positive Hodgkins and Non-hodgkins Lymphona. Primary completion is listed as 2022-03-30.

Are results available for NCT03357757?

neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT03357757.

Back to the full neoantigen vaccine trial tracker — 105 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.